Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...
The European Medicines Agency is looking to simplify the way it approves biosimilars by removing the need for “extensive” clinical data, which would likely cut the cost of entry into the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback